Avalon GloboCare Corp. (NASDAQ:ALBT) Short Interest Update

Avalon GloboCare Corp. (NASDAQ:ALBT) was the recipient of a large decrease in short interest in September. As of September 30th, there was short interest totalling 191,300 shares, a decrease of 36.4% from the September 15th total of 300,700 shares. Currently, 3.2% of the shares of the company are short sold. Based on an average daily volume of 4,450,000 shares, the short-interest ratio is presently 0.0 days.

Avalon GloboCare Stock Performance

Shares of ALBT opened at $0.22 on Friday. Avalon GloboCare has a 12 month low of $0.19 and a 12 month high of $1.44. The firm’s 50 day moving average is $0.27 and its 200-day moving average is $0.34. The stock has a market capitalization of $2.39 million, a PE ratio of -0.15 and a beta of 0.31.

Avalon GloboCare (NASDAQ:ALBT) last posted its quarterly earnings data on Monday, August 19th. The company reported ($0.19) EPS for the quarter. The business had revenue of $0.33 million during the quarter.

About Avalon GloboCare

Avalon GloboCare Corp., together with its subsidiaries, owns and operates commercial real estate properties in the United States and China. The company develops and delivers transformative cellular therapeutics, precision diagnostics, and clinical laboratory services. Its leading candidates are AVA-001, an anti-CD19 CAR-T, which has completed first-in-human clinical trial for relapsed/refractory (R/R) B-cell lymphoblastic leukemia; and AVA-011 that has completed pre-clinical laboratory studies and undergoing IND-enabling process development stage to generate cGMP-grade AVA-011 CAR-T cells.